- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05445934
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
A Phase II/III, Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19
Study Overview
Detailed Description
Coronavirus Disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The infectious agent that causes COVID 19 is a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified during a recent outbreak in December 2019. Patients with COVID-19 have symptoms of fever, cough, and shortness of breath along with non-specific symptoms including myalgia and fatigue.
FB2001 is a small-molecule inhibitor of coronavirus 3CL protease (3CLpro). In two phase I clinical trials, we completed doses of FB2001 that were safe, and were projected to be effective in patients according to its pharmacokinetic profile.
This study is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of FB2001 in hospitalized patients with moderate to severe Coronavirus Disease 2019 (COVID 19). A total of about 1188 subjects are planned to be enrolled. The subjects will be randomized in a 1:1 ratio to FB2001 group or placebo group while both receiving standard of care treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Chengchen Sun
- Phone Number: +86 02569760330
- Email: ccsun@frontierbiotech.com
Study Contact Backup
- Name: Cheng Yao
- Email: yaocheng@frontierbiotech.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Beijing Ditan Hospital Capital Medical University
-
Contact:
- Cuiyun Wu
-
Principal Investigator:
- Ronghua Jin
-
-
Shanghai
-
Shanghai, Shanghai, China
- Recruiting
- Huashan Hospital Fudan University
-
Contact:
- Yunao Zhou
-
Principal Investigator:
- Wenhong Zhang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥18 years old, male or female.
- Subjects hospitalized with moderate to severe COVID-19 with a category 4 or 5 on an 8-category ordinal scale.
- Has laboratory-confirmed COVID-19 infection within 5 days prior to randomization.
- Initial COVID-19 symptom onset within 5 days prior to randomization and ≥1 sign/symptom attributable to COVID-19 within 24 hours before randomization.
- The underlying medical condition was well controlled prior to SARS CoV 2 infection and does not affect daily life.
- Subject who did not receive COVID 19 (primary series or booster) vaccine within the 6 months prior to screening.
- The subject is willing to provide written informed consent to participate in the study after reading the informed consent form and the information provided and has had the opportunity to discuss the study with the Investigator or designee.
- The subject is able to communicate satisfactorily with the Investigator and to participate in, and comply with, the requirements of the study.
- The subject is able to understand the nature of the study and any potential hazards associated with participating in it.
- Negative pregnancy test for female subjects of childbearing potential and female subjects less than 2 years of postmenopause. Women of childbearing potential (WOCBP) and Women of non-childbearing potential are eligible to participate. Both women of childbearing potential and women of non-childbearing potential must use an approved method of birth control and agrees to continue to use this method for the duration of the study and for 30 days after taking the last dose of FB2001.
Exclusion Criteria:
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 30 days after the final dose or who are not willing to use a highly effective method of contraception.
- HIV-infected subjects with viral load greater than 400 copies/mL or CD4 count less than 200 cell/µL from known medical history within past 6 months of the Screening Visit.
- Subject with moderate to severe hepatic impairment or acute liver failure.
- Known severe kidney disease.
- Participated in other intervention studies within 6 months.
- Has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants who are not expected to survive longer than 48 hours after randomization, or participants who are expected to require mechanical ventilation within 48 hours after randomization, or participants with a recent history of mechanical ventilation.
- Subjects receiving any medications or substances that are strong inhibitors or inducers of CYP3A within 14 days of randomization.
- Received, ongoing or planed treatment with other anti-SARS CoV 2 therapeutics (including but not limited to known anti-SARS CoV 2 antibodies, small molecule antivirals, etc., other than remdesivir).
- Other conditions that may increase the risk of study participation or, in the Investigator's judgment, make the participant inappropriate for the study.
- Have known hypersensitivity to FB2001 or its excipients.
- Any planned vaccine within 28 days following the last administration of FB2001 for Injection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FB2001 group
FB2001 will be administered by IV infusion twice daily (BID) for up to 5 days, plus SOC.
|
FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion.
FB2001 will be administered by IV infusion over approximately 60 minutes.
Other Names:
|
Placebo Comparator: Placebo group
Placebo will be administered by IV infusion twice daily (BID) for up to 5 days, plus SOC.
|
Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion.
Placebo will be administered by IV infusion over approximately 60 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to sustained recovery (in days) from randomization up to Day 29.
Time Frame: Up to Day 29
|
Day of sustained recovery is defined as the first day on which a subject is discharged from hospital, or hospitalized for infection-control or other non-medical reasons through Day 29
|
Up to Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with mechanical ventilation or all-cause-death
Time Frame: Through Day 29 and Day 60
|
Proportion of participants with mechanical ventilation or all-cause-death in FB2001 group and placebo group
|
Through Day 29 and Day 60
|
Clinical status category as assessed by an 8-category ordinal scale daily while hospitalized and on Days, 15 and 29.
Time Frame: On Days 15 and 29
|
no specific description
|
On Days 15 and 29
|
Duration of each targeted COVID-19 sign/symptom until discharge
Time Frame: Up to Day 29
|
Duration of each targeted COVID-19 sign/symptom until discharge
|
Up to Day 29
|
Severity of each targeted COVID-19 sign/symptom until discharge
Time Frame: Up to Day 29
|
no specific description
|
Up to Day 29
|
Days of supplemental oxygen (if applicable)
Time Frame: Up to Day 29
|
no specific description
|
Up to Day 29
|
Duration of non-invasive ventilation/high-flow oxygen (if applicable)
Time Frame: Up to Day 29
|
no specific description
|
Up to Day 29
|
Days of invasive mechanical ventilation/ECMO (if applicable)
Time Frame: Up to Day 29
|
no specific description
|
Up to Day 29
|
Time to achieve SARS-CoV-2 virologic clearance
Time Frame: Up to Day 29
|
no specific description
|
Up to Day 29
|
Proportion of participants achieving SARS-CoV-2 virologic clearance on Day 3, 5, 8, 15 and 29
Time Frame: On Day 3, 5, 8, 15 and 29
|
no specific description
|
On Day 3, 5, 8, 15 and 29
|
Viral load change (log10) from baseline on Day 3, 5, 8 and 15.
Time Frame: On Day 3, 5, 8 and 15
|
no specific description
|
On Day 3, 5, 8 and 15
|
Population pharmacokinetic (PK) parameters to be measured/analyzed, including AUC, Cmax and Ctrough
Time Frame: Day0-Day 5
|
no specific descriptionsa
|
Day0-Day 5
|
Proportion of participants with sustained recovery on Day 6
Time Frame: On Day 6
|
no specific description
|
On Day 6
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Up to Day 60
|
safety evaluation
|
Up to Day 60
|
Incidence of withdrawals due to Adverse Events (AEs)
Time Frame: Up to Day 60
|
safety evaluation
|
Up to Day 60
|
Change in vital signs including blood pressure, heart rate, respiratory rate, and temperature from baseline
Time Frame: Up to Day 29
|
safety evaluation
|
Up to Day 29
|
Incidence of Treatment-Related Adverse Events (TRAEs)
Time Frame: Up to Day 60
|
safety evaluation
|
Up to Day 60
|
Incidence of Serious Adverse Events (SAEs)
Time Frame: Up to Day 60
|
safety evaluation
|
Up to Day 60
|
Change/shifts in laboratory values from baseline
Time Frame: Up to Day 29
|
safety evaluation
|
Up to Day 29
|
Change in abnormal Electrocardiogram (ECG) parameters from baseline
Time Frame: Up to Day 29
|
safety evaluation
|
Up to Day 29
|
Changes in abnormal physical examination findings from baseline
Time Frame: Up to Day 29
|
safety evaluation
|
Up to Day 29
|
Change in oxygen saturation (SpO2) from baseline
Time Frame: Up to Day 29
|
safety evaluation
|
Up to Day 29
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Cheng Yao, Frontier Biotechnologies Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FB2001-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on FB2001
-
Frontier Biotechnologies Inc.RecruitingEvaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19Mild to Moderate COVID-19China
-
Frontier Biotechnologies Inc.Completed
-
Frontier Biotechnologies Inc.Completed
-
Frontier Biotechnologies Inc.Completed
-
Ruijin HospitalFrontier Biotechnologies Inc.; Shanghai Center for Disease Control and PreventionNot yet recruitingClose Contact Transmission